Advanced search
Publication Cover
Cancer Investigation Volume 13, 1995 - Issue 1
Submit an article Journal homepage
6
Views
11
CrossRef citations to date
0
Altmetric
Original Article

A Phase II Study of Continuous Infusion of Trimetrexate in Patients with Refractory Acute Leukemia

Albert Kheradpour Program of Molecular Pharmacology and Therapeutics and Departments of Pediatrics and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, New York, 10021; University of Texas Medical Branch, Galveston, TX, 77555
,
Ellin Berman Program of Molecular Pharmacology and Therapeutics and Departments of Pediatrics and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, New York, 10021
,
Erdem Göker Program of Molecular Pharmacology and Therapeutics and Departments of Pediatrics and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, New York, 10021
,
James T. Lin Program of Molecular Pharmacology and Therapeutics and Departments of Pediatrics and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, New York, 10021; University of Texas Medical Branch, Galveston, TX, 77555
,
William P. Tong Program of Molecular Pharmacology and Therapeutics and Departments of Pediatrics and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, New York, 10021
&
Joseph R. Bertino Program of Molecular Pharmacology and Therapeutics and Departments of Pediatrics and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, New York, 10021
Pages 36-40 | Published online: 11 Jun 2009

References

  • Bertino J R, Sawicki W L, Moroson B A. 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino) methyl) quinazoline (TMQ), a potent non-classical folate antagonist inhibitor-1. Biochem Pharmacol 1979; 28: 1983–1987
  • Lin J T, Bertino J R. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest 1991; 9(2)159–172
  • Kamen B A, Eibl B, Cashmore A R. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5 methyl-6-((3,4,5-trimethoxy-anilino) methyl] quinazoline), a non-classical antifolate in meth-otrexate-resistant leukemia cells, in vitro. Biochem Pharmacol 1985; 33: 1697–1699
  • Fry D W, Besserer V A. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 1988; 48: 6986–6991
  • Rodenhuis S, McGuine J J, Sawake W L, Bertino J R. Effect of methotrexate and of the “non classical” folate antagonist trimetrexate on human leukemia cells. Leukemia 1987; 1: 116–120
  • Mini E, Moroson B A, Franco C T, Bertino J R. Cytotoxic effects of folate antagonists against methotrexate-resistant human leuke-mic lymphoblast CCRF-CEM cell lines. Cancer Res 1985; 45: 325–330
  • Lin J, Tong W P, Trippett T M, Niedzwiecki D. Basis for natural resistance to methotrexate in human acute non-lympho-cytic leukemia. Cancer Res 1991; 15: 1191–1196
  • Ohnoshi T, Ohnuma T, Takahaashi I, Scanlon K. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. Cancer Res 1982; 42: 1655–1660
  • Balis F M, Lester C M, Poplack D G. Pharmacokinetics of trimetrexate (NSC352122) in monkeys. Cancer Res 1986; 46: 169–174
  • Balis F M, Patel R, Luks E, Doherty K M. Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 1987; 47: 4973–4976
  • Fanucchi M P, Walsh T D, Fleisher M, Lokos G. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 1987; 47: 3303–3308
  • Stewart J A, McCormack J J, Tong W P, Low J B. Phase I clinical and pharmacokinetic study of trimetrexate using a daily X5 schedule. Cancer Res 1988; 48: 5029–5035
  • Sanders J, Ducore J, Kamen B. A pediatric phase I trial of trimetrexate (TMTX) in children with acute leukemia and solid tumors. Proc Am SOC Clin Oncol 1987; 644, (abstract)
  • Rosen M, Ohnuma T, Zimet A. Phase I study of trimetrexate (TMTX, TMQ. JB-11) glucuronate in a 5 day infusion schedule. Proc Am Assoc Cancer Res 1986; 27: 172, (abstract)
  • Bishop J F, Raghavan D, Olver I N, Reece P. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. Cancer Chemother Pharmacol 1989; 24: 246–250
  • Pappo A, Dubowy R, Ravindranath Y, Alvarado C. Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Natl Cancer Inst 1990; 82(20)164–1642
  • Ackerly C C, Hartshorn J, Tong W P, McCormack J. A rapid and sensitive method for determination of TMTX from biological fluid. J Liquid Chromatogr 1985; 125–134
  • Trippett T, Schlemmer S, Elisseyeff Y, Goker E. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia. Blood 1992; 1158–1162
  • Allegra C J, Chabner B A, Tuzan C V, Araakaki D O. Trimetrexate for the treatment of pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl JMed 1987; 317: 978–985
  • Armstrong R D, Vera R, Snyder L, Cadman E. Enhancement of 6-thioguanine cytotoxic activity with methotrexate. Biochem Biophys Res Commun 1982; 109: 595–601
  • Bokkemik J PM, Bakker M AH, Hulscher T W, Abrev R A. Sequence time and dose dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol 1986; 35: 3549–3555
  • Conti J A, Kemeny N, Goker E, Tong W. A phase I trial of sequential trimetrexate, fluorouracil and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. Proc Am SOC Clin Oncol 1993; 12: 567, (abstract)
  • Tan C, Trippett T, Tong W, Vansyckle K. A pharmacologic guided trial of sequential methotrexate (MTX) and 6-thioguanine (6-TC). Proc Am Assoc Cancer Res 1992; 33: 209
  • Camitta B, Leventbal B, Lauer S, Shuster J J. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 1989; 7: 1539–1544

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.